R
Rodney B. Luwor
Researcher at University of Melbourne
Publications - 84
Citations - 4001
Rodney B. Luwor is an academic researcher from University of Melbourne. The author has contributed to research in topics: Cancer & Metastasis. The author has an hindex of 28, co-authored 76 publications receiving 3356 citations. Previous affiliations of Rodney B. Luwor include Ludwig Institute for Cancer Research & Royal Melbourne Hospital.
Papers
More filters
Journal ArticleDOI
The EGFRvIII variant in glioblastoma multiforme
TL;DR: This review summarizes the current knowledge about the role of EGFRvIII in GBM and discusses therapeutic agents targeting EG FRvIII that are being evaluated as treatments for GBM.
Journal ArticleDOI
Interleukin-11 Is the Dominant IL-6 Family Cytokine during Gastrointestinal Tumorigenesis and Can Be Targeted Therapeutically
Tracy L Putoczki,Tracy L Putoczki,Stefan Thiem,Andrea Loving,Rita A. Busuttil,Rita A. Busuttil,Nicholas J. Wilson,Paul Ziegler,Paul M Nguyen,Adele Preaudet,Ryan Farid,Kirsten Edwards,Yeliz Boglev,Rodney B. Luwor,Andrew G. Jarnicki,David Horst,Alex Boussioutas,Alex Boussioutas,Joan K. Heath,Oliver M. Sieber,Irina Pleines,Benjamin T. Kile,Andrew D. Nash,Florian R. Greten,Brent S. McKenzie,Matthias Ernst,Matthias Ernst +26 more
TL;DR: Using genetic mouse models and in human tumor cell line xenograft models, pharmacologic inhibition of IL-11 signaling alleviated STAT3 activation, suppressed tumor cell proliferation, and reduced the invasive capacity and growth of tumors.
Journal Article
Growth Suppression of Intracranial Xenografted Glioblastomas Overexpressing Mutant Epidermal Growth Factor Receptors by Systemic Administration of Monoclonal Antibody (mAb) 806, a Novel Monoclonal Antibody Directed to the Receptor
Kazuhiko Mishima,Terrance Grant Johns,Rodney B. Luwor,Andrew M. Scott,Elisabeth Stockert,Achim A. Jungbluth,Xiang-Dong Ji,Padma Suvarna,Joseph R. Voland,Lloyd J. Old,H-J. Su Huang,Webster K. Cavenee +11 more
TL;DR: Testing the efficacy of a novel monoclonal anti-DeltaEGFR antibody on the growth of intracranial xenografted gliomas in nude mice provides preclinical evidence that mAb 806 treatment may be a useful biotherapeutic agent for those aggressivegliomas that express DeltaEGFR.
Journal ArticleDOI
Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors
Ardian Latifi,Rodney B. Luwor,Maree Bilandzic,Simon Nazaretian,Kaye L. Stenvers,Jan Pyman,Hong-Jian Zhu,Erik W. Thompson,Michael A. Quinn,Michael A. Quinn,Jock K. Findlay,Jock K. Findlay,Nuzhat Ahmed +12 more
TL;DR: Using a novel purification method, a distinct separation of ascites cells into epithelial tumorigenic and mesenchymal non-tumorigenic populations is demonstrated for the first time and it is demonstrated that cells from the ascites of CR patients are predominantly epithelial and show a trend towards increased mRNA expression of genes associated with CSCs, compared to cells isolated from the Ascites of CN patients.
Journal Article
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Rodney B. Luwor,Terrance Grant Johns,Carmel Murone,H-J. Su Huang,Webster K. Cavenee,Gerd Ritter,Lloyd J. Old,Antony W. Burgess,Andrew M. Scott +8 more
TL;DR: It is demonstrated that mAb 806 possesses significant antitumor activity and offers an advantage over current EGFR antibodies, which all display significant binding to the liver and skin in humans.